TELIX Pharmaceuticals is conducting Phase 3 trials and seeking alignment on the New Drug Application pathway with the FDA.
11 reports, 2 independent
Updated Sep 14
Gone quiet
Reached 4 outlets in its first 24 hours
- Reports
- 11
- Developments
- 2
- Repetition
- 82%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
TELIX Pharmaceuticals is conducting Phase 3 trials and seeking alignment on the New Drug Application pathway with the FDA.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Pixclara, a drug from TELIX, received NDA approval from the FDA for treating brain cancer.1 source
TELIX is running Phase 3 trials and working with the FDA on its NDA pathway.1 source
Keep exploring
The entities involved
-
TELIX PHARMACEUTICALS LIMITED
Australian public company
Nothing else this week.
- FDA
Related events
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- Arise is seeking FDA approval for a drug as of October 7, 2026.
- Yamo Pharmaceuticals LLC plans to conduct a Phase 3 study in the US, with drug development regulated by the FDA.
- EyePoint Pharmaceuticals developed its LUCIA trial program in alignment with the FDA, with enrollment noted in Lugano.
- Cardiff Oncology and Nerviano Medical Sciences are seeking FDA regulatory review for Phase 3 trials and managing a licensing dispute over onvansertib.